Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$14995
Buy Report

Published: December 23, 2024 Report Code: GDHC299PIDR-7M-ST

Select Item

Glaucoma Market Report Overview

The Glaucoma market sales across the 7MM was $2.1 billion in 2023. The sales of glaucoma therapeutics across the 7MM will grow at a compound annual growth rate (CAGR) of more than 2% between 2023 and 2033. Factors such as the surge in the prevalence of glaucoma due to the ageing population and the launch of new products addressing the unmet needs in glaucoma treatment will drive growth in the glaucoma market across the 7MM.

Glaucoma is the leading cause of irreversible vision loss worldwide. There are two main categories of glaucoma, which are defined by the morphology of the anterior chamber angle in the affected eyeball- OAG & ACG. Open-angle glaucoma (OAG) is the most common form, carrying a chronic prognosis and composing 75–95% of primary cases. Angle-closure glaucoma (ACG), in contrast to OAG, is defined by the closing of the iridocorneal angle. It can either be acute or chronic, but typically has a faster progression than OAG and therefore requires more drastic interventions.

Glaucoma Market Outlook, 2023-2033 ($ Billion)

Glaucoma Market Outlook, 2023-2033 ($ Billion)

Buy the Full Report to Know More about the Glaucoma Market Forecast

Download a Free Report Sample

The Glaucoma market research report provides a granular forecast growth analysis for both global and regional markets through 2033. The report covers an exhaustive study of the countries wherein the market is prevalent, leading players, current treatment options, and factors driving the market growth. Furthermore, the pipeline valuation analysis and information on the market’s unmet needs and opportunities will help in determining potential business possibilities.

Market Size (2023) $2.1 billion
CAGR (2023-2033) >2%
Forecast Period 2023-2033
Key Countries ·       The US

·       France

·       Germany

·       Italy

·       Spain

·       The UK

·       Japan
Key Classes ·       Prostaglandin Analogues

·       Fixed-Dose Combination Therapies

·       Beta Blockers

·       Cholinergic Agonist

·       Rho-Kinase Inhibitors
Leading Players ·       Abbvie

·       Alcon

·       Merck

·       Pfizer

·       Santen
Enquire & Decide Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.

Glaucoma Market Segmentation by Countries

A few of the key countries wherein the glaucoma market is prevalent are the US, France, Germany, Italy, Spain, the UK, and Japan. In 2023, the US accounted for the highest glaucoma market share in the 7MM. The high cost associated with branded products will help drive market growth in the US as pipeline products launch in this market throughout the forecast period. As a result, pipeline products will have strong market penetration and will have a significant impact on the overall size of the US glaucoma market after they launch.

Glaucoma Market Analysis by Countries, 2023 (%)

Glaucoma Market Analysis by Countries, 2023 (%)

Buy the Full Report for More Country Insights into the Glaucoma Market

Download a Free Report Sample

Glaucoma Market Segmentation by Classes

A few of the glaucoma classes in the US are Prostaglandin Analogues, Fixed-Dose Combination Therapies, Beta Blockers, Cholinergic Agonist, and Rho-Kinase Inhibitors, among others. In 2023, Prostaglandin Analogues accounted for the highest share of the glaucoma market.

Glaucoma Market Analysis by Classes, 2023 (%)

Glaucoma Market Analysis by Classes, 2023 (%)

Buy the Full Report for More Class Insights into the US Glaucoma Market

Download a Free Report Sample

Glaucoma Market - Competitive Landscape

A few of the major players in the Glaucoma market are:

  • Abbvie
  • Alcon
  • Merck
  • Pfizer
  • Santen

Glaucoma Market Analysis by Players

Glaucoma Market Analysis by Players

Buy the Full Report to Know More about Companies in the Glaucoma Market

Download a Free Report Sample

Segments Covered in the Report

Glaucoma Country Outlook (Value, $ Billion, 2023-2033)

  • The US
  • France
  • Germany
  • Italy
  • Spain
  • The UK
  • Japan

 Glaucoma Class Outlook (Value, $ Billion, 2023-2033)

  • Prostaglandin Analogues
  • Fixed-Dose Combination Therapies
  • Beta Blockers
  • Cholinergic Agonist
  • Rho-Kinase Inhibitors

Scope

The report provides:

  • Overview of glaucoma, including epidemiology, symptoms, diagnosis, and disease management.

  • Annualized glaucoma therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.

  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the glaucoma therapeutics market.

  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for glaucoma treatment. The most promising candidates in late-stage development are profiled.

  • Analysis of the current and future market competition in the global glaucoma therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

  • Develop business strategies by understanding the trends shaping and driving the 7MM glaucoma therapeutics market.

  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM glaucoma therapeutics market in the future.

  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Abbvie
Allergan
Alcon
Pfizer
Merck
Santen
Ocular Therapeutix
pH Pharma
Nicox
DWTI
Thea Pharma
Betaliq
Tarsier Pharma

Table of Contents

List of Contents

About GlobalData

List of Contents

List of Tables

List of Figures

1 Glaucoma: Executive Summary

1.1 The glaucoma market will increase between 2023 and

2033.

1.2 The development of drugs with novel MOAs or routes of administration marks a shift in glaucoma corporate strategy.

1.3 Unmet needs remain for glaucoma, particularly improving patient compliance.

1.4 Late-stage pipeline drugs entering the glaucoma market are poised to drive growth.

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Overview

3.1.2 Etiology

3.1.3 NTG

3.1.4 Pathophysiology

3.2 Classification or staging systems

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities.

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of POAG (excluding NTG)

4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of NTG.

4.4.5 Forecast assumptions and methods: diagnosed prevalent cases of PACG

4.4.6 Forecast assumptions and methods: diagnosed incident cases of acute PACG.

4.4.7 Forecast assumptions and methods: diagnosed prevalent cases of secondary glaucoma.

4.5 Epidemiological forecast for glaucoma (2023–33)

4.5.1 Diagnosed prevalent cases of POAG (excluding NTG)

4.5.2 Age-specific diagnosed prevalent cases of POAG (excluding NTG)

4.5.3 Sex-specific diagnosed prevalent cases of POAG (excluding NTG)

4.5.4 Diagnosed prevalent cases of NTG

4.5.5 Diagnosed prevalent cases of PACG.

4.5.6 Age-specific diagnosed prevalent cases of PACG

4.5.7 Sex-specific diagnosed prevalent cases of PACG

4.5.8 Diagnosed prevalent cases acute and chronic PACG

4.5.9 Diagnosed incident cases of acute PACG

4.5.10 Diagnosed incident cases of secondary glaucoma

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 COVID-19 impact.

4.6.3 Limitations of the analysis

4.6.4 Strengths of the analysis

5 Disease Management

5.1 Diagnosis overview

5.1.1 Ophthalmoscopy

5.1.2 Tonometry

5.1.3 Perimetry

5.1.4 Pachymetry

5.1.5 Gonioscopy

5.2 Treatment overview

5.2.1 Treatment guidelines

5.3 KOL insights on disease management

6 Current Treatment Options

6.1 Overview

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved patient compliance

7.3 Treatments with better IOP lowering-ability

7.4 Novel drug delivery systems

7.5 Neuroprotective drugs

7.6 Improved diagnosis and monitoring

8 R&D Strategies

8.1 Overview

8.1.1 New IOP-lowering drugs

8.1.2 Implants in glaucoma

8.2 Clinical trials design

8.2.1 Clinical endpoints for glaucoma

8.2.2 Inclusion and exclusion criteria

9 Pipeline Assessment

9.1 Overview

9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global (7MM) issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting methodology

13.4 Primary research – KOLs interviewed for this report.

13.4.1 KOLs

13.5 Primary research – prescriber survey

13.6 About the authors

13.6.1 Analyst

13.6.2 Therapy Area Director

13.6.3 Epidemiologist

13.6.4 Reviewers, epidemiology

13.6.5 Vice President of Disease Intelligence and Epidemiology

13.6.6 Global Head of Pharma Research, Analysis, and Competitive Intelligence

Contact Us

Table

Table 1: Glaucoma: Key metrics in the 7MM

Table 2: The different causes of secondary glaucoma

Table 3: Classification of glaucoma by ICD-10 codes

Table 4: Classification of glaucoma by primary and secondary groups

Table 5: Classification of glaucoma by OAG and ACG sub-types

Table 6: Risk factors and comorbidities for glaucoma

Table 7: Diagnostic tests for glaucoma

Table 8: Ophthalmologic imaging techniques

Table 9: Treatment guidelines for glaucoma

Table 10: Top 10 deals by value, 2019–24

Table 11: Glaucoma market – global (7MM) drivers and barriers, 2023–33

Table 12: Key events impacting sales for glaucoma in the US, 2023–33

Table 13: Glaucoma market – drivers and barriers in the US, 2023–33

Table 14: Key events impacting sales for glaucoma in the 5EU, 2023–33

Table 15: Glaucoma market – drivers and barriers in the 5EU, 2023–33

Table 16: Key events impacting sales for glaucoma in Japan, 2023–33

Table 17: Glaucoma market – drivers and barriers in Japan, 2023–33

Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for glaucoma in 2023 and 2033

Figure 2: Analysis of the company portfolio gap in glaucoma during the forecast period

Figure 3: Competitive assessment of the late-stage pipeline agents that GlobalData expects to be licensed for the treatment of glaucoma during the forecast period

Figure 4: The AqH flow in OAG and ACG

Figure 5: The AqH Cycle

Figure 6: 7MM, diagnosed prevalence of POAG (including NTG), both sexes, %, ages ≥40 years, 2023

Figure 7: 7MM, diagnosed prevalence of POAG (excluding NTG), both sexes, %, ages ≥40 years, 2023

Figure 8: 7MM, diagnosed prevalence of PACG, both sexes, %, ages ≥40 years, 2023

Figure 9: 7MM, sources used and not used to forecast the diagnosed prevalent cases of POAG (excluding NTG)

Figure 10: 7MM, sources used to forecast the diagnosed prevalent cases of NTG

Figure 11: 7MM, sources used to forecast the diagnosed prevalent cases of PACG

Figure 12: 7MM, sources used to forecast the diagnosed incident cases of acute PACG

Figure 13: 7MM, sources used to forecast the diagnosed prevalent cases of secondary glaucoma

Figure 14: 7MM, diagnosed prevalent cases of POAG (excluding NTG), N, both sexes, ages ≥40 Years, 2023

Figure 15: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by age, N, both sexes, 2023

Figure 16: 7MM, diagnosed prevalent cases of POAG (excluding NTG) by sex, N, ages ≥40 Years, 2023

Figure 17: 7MM, diagnosed prevalent cases of NTG, N, both sexes, ages ≥40 years, 2023

Figure 18: 7MM, diagnosed prevalent cases of PACG, N, both sexes, ages ≥40 years, 2023

Figure 19: 7MM, diagnosed prevalent cases of PACG by age, N, both sexes, 2023

Figure 20: 7MM, diagnosed prevalent cases of PACG by sex, N, both sexes, ages ≥40 Years, 2023

Figure 21: 7MM, diagnosed prevalent cases of acute and chronic PACG, N, both sexes, ages ≥40 years, 2023

Figure 22: 7MM, diagnosed incident cases of acute PACG, N, both sexes, ages ≥40 years, 2023

Figure 23: 7MM, diagnosed prevalent cases of secondary glaucoma, N, both sexes, ages ≥40 years, 2023

Figure 24: Unmet needs and opportunities in glaucoma

Figure 25: Overview of the development pipeline in glaucoma

Figure 26: Key late-stage trials for the promising pipeline agents that GlobalData expects be licensed for glaucoma in the 7MM during the forecast period

Figure 27: Competitive assessment of the promising pipeline agents that GlobalData expects to be licensed for glaucoma in the 7MM during the forecast period

Figure 28: Competitive assessment of the marketed and pipeline drugs benchmarked against the SOC, latanoprost

Figure 29: Analysis of the company portfolio gap in glaucoma during the forecast period

Figure 30: Global (7MM) sales forecast by country for glaucoma in 2023 and 2033

Figure 31: Sales forecast by class for glaucoma in the US in 2023 and 2033

Figure 32: Sales forecast by class for glaucoma in the 5EU in 2023 and 2033

Figure 33: Sales forecast by class for glaucoma in Japan in 2023 and 2033

Frequently asked questions

Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 standard reports
Currency USD
$14,995

Can be used by individual purchaser only

Most Popular
$29,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$44,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Glaucoma reports
Pharmaceuticals
New
Focal Segmental Glomerulosclerosis (FSGS): Market View, Current and Future Competitive…
$3,495 | July 2026
Pharmaceuticals
New
Reflux Esophagitis (Gastroesophageal Reflux Disease): Market View, Current and Future…
$3,495 | June 2026
Pharmaceuticals
New
IgA Nephropathy (Berger’s Disease): Market View, Current and Future Competitive…
$3,495 | June 2026
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 in real time.

  • Access a live Glaucoma in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more